Aldevron has added six new employees in its Fargo location, including Steve Chalfant, Pragya Dahal, Maureen Krogstad, Audra Puppe, David Fellen and Michael Schmidt.
Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.
Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services, announces the availability of GMP-grade SpCas9 nuclease for use in clinical development programs. Aldevron’s GMP SpCas9 is designed to accelerate gene editing clinical trials and commercial applications by providing an immediate enzyme supply; thereby eliminating months typically associated with contract GMP production and testing.
Aldevron, a global provider of plasmid DNA and gene editing enzymes used to support novel cancer therapies, will be a Platinum sponsor of the 2017 Believe Ball organized by the Emily Whitehead Foundation. In its inaugural year, the Believe Ball will bring together T-Cell therapy patients and their families with the doctors, scientists, researchers, and others who helped develop this therapy.
Thomas Lynch, Ph.D., has been named Vice President of Sales and Client Development of Aldevron. Lynch will guide the sales strategy and growth for Aldevron’s product lines in nucleic acids, proteins, and antibodies. His responsibilities include growing the company’s sales team to further support Aldevron’s worldwide preclinical and GMP client base.